Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

Key Points Exact Sciences has the potential to be a big name in cancer testing and screening in the future. It already has multiple tests, and is working on one that can screen for multiple cancers.

Exact Sciences Corporation EXAS is well poised for growth in the coming quarters, led by strong Cologuard growth. The raised 2023 guidance is a major upside. However, mounting expenses and stiff ...

Exact Sciences is beginning to stem losses and is continuing to grow revenue at a reasonable clip. Despite this, GAAP profitability is still far into the future, and the 2023 guidance is mediocre.

Last year, Exact Sciences burned through $223.6 million in cash just from its day-to-day operations. And that was a significant increase from the $102.2 million it used up in the previous year.

First, more providers than ever are now prescribing Cologuard. Exact Sciences recently reported that around 147,000 providers have adopted the DNA cancer test, which reflects a CAGR of 76% since 2014.

A n updated version of Exact Sciences’ stool-based colorectal cancer screening test detected cancer accurately in a massive study, triggering fewer false alarms than its current product, the ...